OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Quote | OKYO Pharma Limited (NASDAQ:OKYO)
Last: | $1.21 |
---|---|
Change Percent: | 1.61% |
Open: | $1.22 |
Close: | $1.21 |
High: | $1.22 |
Low: | $1.19 |
Volume: | 7,023 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | OKYO Pharma Limited (NASDAQ:OKYO)
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases ...
Message Board Posts | OKYO Pharma Limited (NASDAQ:OKYO)
Subject | By | Source | When |
---|---|---|---|
Big volume, just needed to take a breathe | mfayman | investorshub | 10/05/2023 3:53:59 PM |
Will end up green today | Sirpeter | investorshub | 10/05/2023 3:26:10 PM |
Will be over $3 by Monday... | Sirpeter | investorshub | 10/05/2023 2:24:52 PM |
Got to add down here...could be a $75-100 | Sirpeter | investorshub | 10/05/2023 2:09:11 PM |
..thought it make $3..sell the news, terrible.. $OKYO$... | Pisd | investorshub | 10/05/2023 2:04:57 PM |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases ...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment disease...